Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
10.4166/kjg.2020.75.2.103
- Author:
Se Woong CHOI
1
;
Jeong Min LEE
;
Dong Gyun KIM
;
Myung Hwan NOH
Author Information
1. Department of Internal Medicine, Good Gang-An Hospital, Busan, Korea.
- Publication Type:Case Report
- Keywords:
Acalculous cholecystitis;
Sunitinib;
Renal cell carcinoma
- MeSH:
Acalculous Cholecystitis;
Anti-Bacterial Agents;
Carcinoma, Renal Cell;
Cholecystitis, Acute;
Cholecystostomy;
Disseminated Intravascular Coagulation;
Drug-Related Side Effects and Adverse Reactions;
Fever;
Humans;
Middle Aged;
Nausea;
Ultrasonography;
Vomiting
- From:The Korean Journal of Gastroenterology
2020;75(2):103-107
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 64-year-old man was treated with sunitinib as a first-line therapy for metastatic renal cell carcinoma. He was given oral sunitinib in cycles of 50 mg once daily for 2 weeks followed by a week off. During the 5th week of treatment right upper quadrant pain developed, but this resolved spontaneously during the 6th week (off treatment). However, on the 8th week of treatment, he was admitted to hospital because the acute right upper quadrant pain recurred with nausea, vomiting, and fever. Acute acalculous cholecystitis was then diagnosed by ultrasonography and CT. In addition, his laboratory findings indicated disseminated intravascular coagulation. Accordingly, sunitinib therapy was discontinued and broad-spectrum antibiotics initiated. He subsequently recovered after emergent percutaneous cholecystostomy. His Naranjo Adverse Drug Reaction Probability Scale score was 7, indicaing a probable association of the event with sunitinib. Suspicion of sunitinib-related acute cholecystitis is required, because, although uncommon, it can be life-threatening.
